BioMarin adopts amended bylaws with DGCL alignment and universal proxy rule updates

BIOMARIN PHARMACEUTICAL INC

Board approved amended bylaws effective Dec 15, 2022, updating notice and meeting adjournment to align with DGCL.
Requires stockholders soliciting proxies to use a proxy card color other than white.
Amends procedural mechanics for stockholder nominations and proposals under SEC Rule 14a-19 (Universal Proxy Rules).
Includes administrative, modernizing, and clarifying changes to the bylaws.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

BIOMARIN PHARMACEUTICAL INC: Amended and restated bylaws to update provisions related to stockholder meetings, proxy rules, and other administrative changes (effective 2022-12-15).

Change: bylaw amendment
Effective: 2022-12-15

Exact text from the filing

On December 15, 2022, the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”) approved and adopted the Company’s Amended and Restated Bylaws (as so amended, the “Amended Bylaws”), effective as of December 15, 2022.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001193125-22-310054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.